1	and/or	nunt infection by Emergency Department physician based on presence of ≥ 1 risk factors for shunt infection ¹	dinical judgment	¹ Risk Factors for Shunt Infection
	Exclusion	Criteria: alternative source for fever identified		Shunt
	Notify Neuros	urgery attending at first suspicion of shunt infection		surgery
	Noury Neuros	TRIAGE:		within
• Vi	ital signs a1hr then a2hr when more	stable: temperature, BP, HR, RR, O2 sat, neuro check		previous 6
	/eight, head circumference (for <12			months
	lace on continuous CR monitoring	,		Clinical signs
		immediately if bradycardia, hypertension or depressed LOC	is noted*	ofinfection
	Obtain	detailed history/initial exam: See Appendix A.		involving shunt
		*		hardware
		INITIAL MANAGEMENT:		including
Labs:				skin erosion,
		tonin, blood culture, UA, urine culture		cellulitis,
	hunt tap by NSG: send STAT CSF for o	ell count, glucose, protein, gram stain, aerobic culture and a	naerobic culture	incisional
Imaging:	- I I - I	han the state of the second of the second state of	and the second	drainage or
		hout contrast is preferred if imaging modality if confirmation		abdominal
	hunt Valves)	ted in chart, may confirm via skull x-ray; Appendix B: Radiog	raphic Appearance of	pseudocyst
0	,	t: prior to ordering MRI, please ensure a Neurosurgery provi	der is able to reprogram	 Clinical signs
0		ging. Make MRI aware that patient has a programmable shu		ofmeningiti
0				 No other
		abdominal symptoms: limited ultrasound of abdomen		obvious
	large or complex pseudocyst of t			source of
Antibiotics a				fever
		ter obtaining blood culture, UA/urine culture, and CSF cultur	e, if possible:	 Previous
0		divided q8hr (max 2 g/dose) <u>AND</u>		shunt
0		[‡] /about <3 mo old: 15 mg/kg q8hr or as determined by phar	macy based on estimated	infection
Ĭ		months old – 11 years old: 70 mg/kg/day div q6hr; \geq 12 yrs o		L
• N		th 0.45 or 0.9% NaCl depending on serum Na levels)	0 0 ··· / ··· 10	
	Menstrual Age) = gestational age + p			
		•	_ /	
	Pre-0	<u>Op:</u> Admit to PICU on Neurosurgery service		ney Injury (AKI) based on the
	OR case reque	est for externalization (Neurosurgery to obtain consent for O		wing criteria: a creatinine by 1.5-1.9 times
		R monitoring (close monitoring for bradycardia)	baseline within th	ne priorseven days, or
	Continue NPC			creatinine by ≥0.3 mg/dL from
		Post-Op: admit back to PICU	For those with un	ncmol/L) within 48 hours, or Iknown creatin in e, an eGFR <90
	EVD/external	zed shunt parameters per surgeon; follow post-op care belo	W ml/min/1.73m ²	
			\	
×	×	×	×	×
ntibiotics	Labs/Monitoring	Pain/Fever	FEN/GI	Other
			PEN/GI	Other
¥ I				V
¥	Labs:	If acute kidney injury ² : Avoid NSAIDs or discuss with	IVF:	
	 CSF studies: cell count and 	Nephrology for approval.	IVF: • Maintenance IVF	OT/PT: activity f
ectious	 CSF studies: cell count and culture to lab per 	Nephrology for approval. • Toradol N 0.5 mg/kg/dose q6hr (max 30 mg/dose)	IVF: • Maintenance IVF • NS 1:1 replacement	OT/PT: activity include OOB with
ectious ease (ID)	 CSF studies: cell count and culture to lab per Neurosurgery and/or ID 	 Nephrology for approval. Toradol N 0.5 mg/kg/dose q6hr (max 30 mg/dose) x6 doses 	 IVF: Maintenance IVF NS 1:1 replacement with CSF output 	OT/PT: activity include OOB wit EVD clamped for
ectious sease (ID) ntinue empiric	 CSF studies: cell count and culture to lab per Neurosurgery and/or ID If CSF culture positive, repeat 	 Nephrology for approval. Toradol IV 0.5 mg/kg/dose q6hr (max 30 mg/dose) x6 doses 6 hours after last toradol dose, start 	IVF: • Maintenance IVF • NS 1:1 replacement with CSF output Medications:	OT/PT: activity include OOB wi EVD clamped fo therapies if stab
ectious sease (ID) ntinue empiric tibiotics	 CSF studies: cell count and culture to lab per Neurosurgery and/or ID If CSF culture positive, repeat in 24-36 hours to document 	 Nephrology for approval. Toradol N 0.5 mg/kg/dose q6hr (max 30 mg/dose) x6 doses o 6 hours after last toradol dose, start ibuprofen PO 10 mg/kg/dose q6hr PRN (max 	IVF: • Maintenance IVF • NS 1:1 replacement with CSF output Medications: • Ondansetron 0.1	OT/PT: activity include OOB wit EVD clamped fo therapies if stat and tolerating
ectious iease (ID) ntinue empiric tibiotics a ncomycin	 CSF studies: cell count and culture to lab per Neurosurgery and/or ID If CSF culture positive, repeat in 24-36 hours to document sterilization. 	Nephrology for approval. • Toradol IV 0.5 mg/kg/dose q6hr (max 30 mg/dose) x6 doses o • 6 hours after last toradol dose, start ibuprofen PO 10 mg/kg/dose q6hr PRN (max 40 mg/kg/day or 2,400 mg/day, whichever is	IVF: • Maintenance IVF • NS 1:1 replacement with CSF output Medications: • Ondansetron 0.1 mg/kg/dose q8hr	OT/PT: activity include OOB wit EVD clamped for therapies if stat and tolerating clamping
ectious sease (ID) ntinue empiric tibiotics ancomycin d Ceftazidime)	 CSF studies: cell count and culture to lab per Neurosurgery and/or ID If CSF culture positive, repeat in 24-36 hours to document sterilization. If persistently febrile or clinica 	Nephrology for approval. Toradol IV 0.5 mg/kg/dose q6hr (max 30 mg/dose) x6 doses o 6 hours after last toradol dose, start ibuprofen PO 10 mg/kg/dose q6hr PRN (max 40 mg/kg/day or 2,400 mg/day, whichever is less)	IVF: Maintenance IVF NS 1:1 replacement with CSF output Medications: Ondansetron 0.1 mg/kg/dose q8hr (max 4 mg/dose)	OT/PT: activity include OOB wit EVD clamped for therapies if stat and tolerating clamping SCD/compression
ectious tease (ID) ntinue empiric tibiotics ancomycin d Ceftazidime) 4 hours or per	 CSF studies: cell count and culture to lab per Neurosurgery and/or ID If CSF culture positive, repeat in 24-36 hours to document sterilization. If persistently febrile or clinica deterioration: repeat CSF 	 Nephrology for approval. Toradol IV 0.5 mg/kg/dose q6hr (max 30 mg/dose) x6 doses 6 hours after last toradol dose, start ibuprofen PO 10 mg/kg/dose q6hr PRN (max 40 mg/kg/day or 2,400 mg/day, whichever is less) Acetaminophen IV 15 mg/kg/dose q6hr ATC for 24 	IVF: Maintenance IVF NS 1:1 replacement with CSF output Medications: Ondansetron 0.1 mg/kg/dose q8hr (max 4 mg/dose) PRN nausea/	 OT/PT: activity include OOB will EVD clamped for therapies if stat and tolerating clamping SCD/compressit boots for DVT p
ectious sease (ID) ntinue empiric tibiotics ancomycin d Ceftazidime) 4 hours or per recs	 CSF studies: cell count and culture to lab per Neurosurgery and/or ID If CSF culture positive, repeat in 24-36 hours to document sterilization. If persistently febrile or clinica deterioration: repeat CSF culture is warranted. Consider 	 Nephrology for approval. Toradol IV 0.5 mg/kg/dose q6hr (max 30 mg/dose) x6 doses 6 hours after last toradol dose, start ibuprofen PO 10 mg/kg/dose q6hr PRN (max 40 mg/kg/day or 2,400 mg/day, whichever is less) Acetaminophen IV 15 mg/kg/dose q6hr ATC for 24 hours (max 1,000 mg/dose) 	IVF: Maintenance IVF NS 1:1 replacement with CSF output Medications: Ondansetron 0.1 mg/kg/dose q8hr (max 4 mg/dose) PRN nausea/ vomiting	 OT/PT: activity include OOB will EVD clamped for therapies if state and tolerating clamping SCD/compression boots for DVT p per hospital pol
ectious ease (ID) ntinue empiric tibiotics ancomycin d Ceftazidime) I hours or per recs just	 CSF studies: cell count and culture to lab per Neurosurgery and/or ID If CSF culture positive, repeat in 24-36 hours to document sterilization. If persistently febrile or clinica deterioration: repeat CSF culture is warranted. Consider blood, urine and respiratory 	 Nephrology for approval. Toradol IV 0.5 mg/kg/dose q6hr (max 30 mg/dose) x6 doses 6 hours after last toradol dose, start ibuprofen PO 10 mg/kg/dose q6hr PRN (max 40 mg/kg/day or 2,400 mg/day, whichever is less) Acetaminophen IV 15 mg/kg/dose q6hr ATC for 24 hours (max 1,000 mg/dose) After 24 hours of IV acetaminophen, switch 	IVF: Maintenance IVF NS 1:1 replacement with CSF output Medications: Ondansetron 0.1 mg/kg/dose q8hr (max 4 mg/dose) PRN nausea/ vomiting Polyethylene	 OT/PT: activity include OOB wi EVD clamped for therapies if stat and tolerating clamping SCD/compressi boots for DVT p per hospital pol Incentive
ectious ease (ID) ntinue empiric tibiotics ancomycin d Ceftazidime) 4 hours or per recs just tibiotics based	 CSF studies: cell count and culture to lab per Neurosurgery and/or ID If CSF culture positive, repeat in 24-36 hours to document sterilization. If persistently febrile or clinica deterioration: repeat CSF culture is warranted. Consider blood, urine and respiratory evaluation. 	 Nephrology for approval. Toradol IV 0.5 mg/kg/dose q6hr (max 30 mg/dose) x6 doses 6 hours after last toradol dose, start ibuprofen PO 10 mg/kg/dose q6hr PRN (max 40 mg/kg/day or 2,400 mg/day, whichever is less) Acetaminophen IV 15 mg/kg/dose q6hr ATC for 24 hours (max 1,000 mg/dose) After 24 hours of IV acetaminophen, switch to PO acetaminophen: 15 mg/kg/dose q6hr 	IVF: Maintenance IVF NS 1:1 replacement with CSF output Medications: Ondansetron 0.1 mg/kg/dose q8hr (max 4 mg/dose) PRN nausea/ vomiting Polyethylene glycol 17 g daily or	 OT/PT: activity include OOB wit EVD clamped for therapies if stat and tolerating clamping SCD/compressit boots for DVT p per hospital pol Incentive spirometer or
ectious sea se (ID) ntinue empiric tibiotics ancomycin d Ceftazidime) 4 hours or per recs just tibiotics based culture and ID	 CSF studies: cell count and culture to lab per Neurosurgery and/or ID If CSF culture positive, repeat in 24-36 hours to document sterilization. If persistently febrile or clinica deterioration: repeat CSF culture is warranted. Consider blood, urine and respiratory evaluation. Monitoring: 	 Nephrology for approval. Toradol IV 0.5 mg/kg/dose q6hr (max 30 mg/dose) x6 doses 6 hours after last toradol dose, start ibuprofen PO 10 mg/kg/dose q6hr PRN (max 40 mg/kg/day or 2,400 mg/day, whichever is less) Acetaminophen IV 15 mg/kg/dose q6hr ATC for 24 hours (max 1,000 mg/dose) After 24 hours of IV acetaminophen, switch to PO acetaminophen: 15 mg/kg/dose q6hr PRN pain; (max 75 mg/kg/day or 4,000 mg/ 	IVF: Maintenance IVF NS 1:1 replacement with CSF output Medications: Ondansetron 0.1 mg/kg/dose q8hr (max 4 mg/dose) PRN nausea/ vomiting Polyethylene glycol 17 g daily or BID PRN	 OT/PT: activity i include OOB wit EVD clamped for therapies if stat and tolerating clamping SCD/compressic boots for DVT p per hospital pol Incentive spirometer or bubbles for
ectious ease (ID) ntinue empiric tibiotics ancomycin d Ceftazidime) 4 hours or per recs just tibiotics based culture and ID cs	 CSF studies: cell count and culture to lab per Neurosurgery and/or ID If CSF culture positive, repeat in 24-36 hours to document sterilization. If persistently febrile or clinica deterioration: repeat CSF culture is warranted. Consider blood, urine and respiratory evaluation. Monitoring: Continuous CR monitoring 	 Nephrology for approval. Toradol IV 0.5 mg/kg/dose q6hr (max 30 mg/dose) x6 doses 6 hours after last toradol dose, start ibuprofen PO 10 mg/kg/dose q6hr PRN (max 40 mg/kg/day or 2,400 mg/day, whichever is less) Acetaminophen IV 15 mg/kg/dose q6hr ATC for 24 hours (max 1,000 mg/dose) After 24 hours of IV acetaminophen, switch to PO acetaminophen: 15 mg/kg/dose q6hr PRN kg/dose q6hr PRN pRN pain; (max 75 mg/kg/dosy or 4,000 mg/day) for mild/moderate pain; may use PR 	IVF: Maintenance IVF NS 1:1 replacement with CSF output Medications: Ondansetron 0.1 mg/kg/dose q8hr (max 4 mg/dose) PRN nausea/ vomiting Polyethylene glycol 17 g daily or BID PRN constipation	 OT/PT: activity include OOB will EVD clamped for therapies if stat and tolerating clamping SCD/compressit boots for DVT p per hospital pol Incentive spirometer or bubbles for atelectasis/PNA
ectious ease (D) htinue empiric biotics uncomycin d Ceftazidime) H hours or per recs just biotics based culture and ID s s antibiotics	 CSF studies: cell count and culture to lab per Neurosurgery and/or ID If CSF culture positive, repeat in 24-36 hours to document sterilization. If persistently febrile or clinica deterioration: repeat CSF culture is warranted. Consider blood, urine and respiratory evaluation. Monitoring: Continuous CR monitoring Vitals q1hr if unstable; q2hr in 	 Nephrology for approval. Toradol IV 0.5 mg/kg/dose q6hr (max 30 mg/dose) x6 doses 6 hours after last toradol dose, start ibuprofen PO 10 mg/kg/dose q6hr PRN (max 40 mg/kg/day or 2,400 mg/day, whichever is less) Acetaminophen IV 15 mg/kg/dose q6hr ATC for 24 hours (max 1,000 mg/dose) After 24 hours of IV acetaminophen, switch to PO acetaminophen: 15 mg/kg/day or 4,000 mg/day) for mild/moderate pain; may use PR acetaminophen for infants. 	IVF: Maintenance IVF NS 1:1 replacement with CSF output Medications: Ondansetron 0.1 mg/kg/dose q8hr (max 4 mg/dose) PRN nausea/ vomiting Polyethylene glycol 17 g daily or BID PRN constipation Docusate sodium	 OT/PT: activity 1 include OOB wit EVD clamped fo therapies if stat and tolerating clamping SCD/compressid boots for DVT p per hospital pol Incentive spirometer or
ectious ease (ID) titue empiric libiotics ncomycin d Ceftazidime) hours or per ecs ust ibiotics based culture and ID s antibiotics , consider	 CSF studies: cell count and culture to lab per Neurosurgery and/or ID If CSF culture positive, repeat in 24-36 hours to document sterilization. If persistently febrile or clinica deterioration: repeat CSF culture is warranted. Consider blood, urine and respiratory evaluation. Monitoring: Continuous CR monitoring 	 Nephrology for approval. Toradol IV 0.5 mg/kg/dose q6hr (max 30 mg/dose) x6 doses 6 hours after last toradol dose, start ibuprofen PO 10 mg/kg/dose q6hr PRN (max 40 mg/kg/day or 2,400 mg/day, whichever is less) Acetaminophen IV 15 mg/kg/dose q6hr ATC for 24 hours (max 1,000 mg/dose) After 24 hours of IV acetaminophen, switch to PO acetaminophen: 15 mg/kg/dose q6hr PRN pain; (max 75 mg/kg/day or 4,000 mg/day) for mild/moderate pain; may use PR acetaminophen for infants. Morphine IV 0.05 – 0.1 mg/kg/dose IV q3hr PRN 	IVF: Maintenance IVF NS 1:1 replacement with CSF output Medications: Ondansetron 0.1 mg/kg/dose q8hr (max 4 mg/dose) PRN nausea/ vomiting Polyethylene glycol 17 g daily or BID PRN constipation Docusate sodium 50 mg/day PRN	 OT/PT: activity include OOB wi EVD clamped for therapies if stal and tolerating clamping SCD/compressi boots for DVT p per hospital pol Incentive spirometer or bubbles for atelectasis/PNA
ectious ease (ID) titue empiric libiotics ncomycin d Ceftazidime) hours or per ecs ust ibiotics based culture and ID s antibiotics , consider	 CSF studies: cell count and culture to lab per Neurosurgery and/or ID If CSF culture positive, repeat in 24-36 hours to document sterilization. If persistently febrile or clinica deterioration: repeat CSF culture is warranted. Consider blood, urine and respiratory evaluation. Monitoring: Continuous CR monitoring Vitals q1hr if unstable; q2hr in PICU if stable; q4hr on MS 	 Nephrology for approval. Toradol IV 0.5 mg/kg/dose q6hr (max 30 mg/dose) x6 doses 6 hours after last toradol dose, start ibuprofen PO 10 mg/kg/dose q6hr PRN (max 40 mg/kg/day or 2,400 mg/day, whichever is less) Acetaminophen IV 15 mg/kg/dose q6hr ATC for 24 hours (max 1,000 mg/dose) After 24 hours of IV acetaminophen, switch to PO acetaminophen: 15 mg/kg/day or 4,000 mg/day) for mild/moderate pain; may use PR acetaminophen for infants. 	IVF: Maintenance IVF NS 1:1 replacement with CSF output Medications: Ondansetron 0.1 mg/kg/dose q8hr (max 4 mg/dose) PRN nausea/ vomiting Polyethylene glycol 17 g daily or BID PRN constipation Docusate sodium	 OT/PT: activity include OOB wi EVD clamped for therapies if stat and tolerating clamping SCD/compressi boots for DVT p per hospital pol Incentive spirometer or bubbles for atelectasis/PNA
actious ease (ID) titue empiric ibiotics ncomycin d Ceftazidime) hours or per recs ust ibiotics based culture and ID s antibiotics l, consider	 CSF studies: cell count and culture to lab per Neurosurgery and/or ID If CSF culture positive, repeat in 24-36 hours to document sterilization. If persistently febrile or clinica deterioration: repeat CSF culture is warranted. Consider blood, urine and respiratory evaluation. Monitoring: Continuous CR monitoring Vitals q1hr if unstable; q2hr in PICU if stable; q4hr on MS 	 Nephrology for approval. Toradol IV 0.5 mg/kg/dose q6hr (max 30 mg/dose) x6 doses 6 hours after last toradol dose, start ibuprofen PO 10 mg/kg/dose q6hr PRN (max 40 mg/kg/day or 2,400 mg/day, whichever is less) Acetaminophen IV 15 mg/kg/dose q6hr ATC for 24 hours (max 1,000 mg/dose) After 24 hours of IV acetaminophen, switch to PO acetaminophen: 15 mg/kg/dose q6hr PRN pain; (max 75 mg/kg/day or 4,000 mg/day) for mild/moderate pain; may use PR acetaminophen for infants. Morphine IV 0.05 – 0.1 mg/kg/dose IV q3hr PRN 	IVF: Maintenance IVF NS 1:1 replacement with CSF output Medications: Ondansetron 0.1 mg/kg/dose q8hr (max 4 mg/dose) PRN nausea/ vomiting Polyethylene glycol 17 g daily or BID PRN constipation Docusate sodium 50 mg/day PRN	 OT/PT: activity include OOB wi EVD clamped for therapies if stat and tolerating clamping SCD/compressi boots for DVT p per hospital pol Incentive spirometer or bubbles for atelectasis/PNA
ectious ease (ID) ntinue empiric jbiotics incomycin d Ceftazidime) H hours or per recs just ibiotics based culture and ID s anthibiotics I, consider m IV access.	 CSF studies: cell count and culture to lab per Neurosurgery and/or ID If CSF culture positive, repeat in 24-36 hours to document sterilization. If persistently febrile or clinica deterioration: repeat CSF culture is warranted. Consider blood, urine and respiratory evaluation. Monitoring: Continuous CR monitoring Vitals q1hr if unstable; q2hr in PICU if stable; q4hr on MS floors 	Nephrology for approval. • Toradol IV 0.5 mg/kg/dose q6hr (max 30 mg/dose) x6 doses • 6 hours after last toradol dose, start ibuprofen PO 10 mg/kg/dose q6hr PRN (max 40 mg/kg/day or 2,400 mg/day, whichever is less) • Acetaminophen IV 15 mg/kg/dose q6hr ATC for 24 hours (max 1,000 mg/dose) • After 24 hours of IV acetaminophen, switch to PO acetaminophen: 15 mg/kg/dose q6hr PRN pain; (max 75 mg/kg/day or 4,000 mg/day) for mid/moderate pain; may use PR acetaminophen for infants. • Morphine IV 0.05 – 0.1 mg/kg/dose IV q3hr PRN severe pain (max 5 mg/dose)	IVF: Maintenance IVF NS 1:1 replacement with CSF output Medications: Ondansetron 0.1 mg/kg/dose q8hr (max 4 mg/dose) PRN nausea/ vomiting Polyethylene glycol 17 g daily or BID PRN constipation Docusate sodium 50 mg/day PRN constipation	 OT/PT: activity include OOB wite EVD clamped for therapies if state and tolerating clamping SCD/compressite boots for DVT pper hospital pol Incentive spirometer or bubbles for atelectasis/PNA prevention
ectious ease (ID) ntinue empiric jbiotics incomycin d Ceftazidime) H hours or per recs just ibiotics based culture and ID s anthibiotics I, consider m IV access.	 CSF studies: cell count and culture to lab per Neurosurgery and/or ID If CSF culture positive, repeat in 24-36 hours to document sterilization. If persistently febrile or clinica deterioration: repeat CSF culture is warranted. Consider blood, urine and respiratory evaluation. Monitoring: Continuous CR monitoring Vitals q1hr if unstable; q2hr in PICU if stable; q4hr on MS floors 	Nephrology for approval. • Toradol IV 0.5 mg/kg/dose q6hr (max 30 mg/dose) x6 doses • 6 hours after last toradol dose, start ibuprofen PO 10 mg/kg/dose q6hr PRN (max 40 mg/kg/day or 2,400 mg/day, whichever is less) • Acetaminophen IV 15 mg/kg/dose q6hr ATC for 24 hours (max 1,000 mg/dose) • After 24 hours of IV acetaminophen, switch to PO acetaminophen: 15 mg/kg/dose q6hr PRN pain; (max 75 mg/kg/dose 1V q3hr PRN severe pain (max 5 mg/kg/dose IV q3hr PRN severe pain (max 5 mg/kg/dose IV q3hr PRN severe pain (max 5 mg/dose) • Morphine IV 0.05 – 0.1 mg/kg/dose IV q3hr PRN severe pain (max 5 mg/dose)	IVF: Maintenance IVF NS 1:1 replacement with CSF output Medications: Ondansetron 0.1 mg/kg/dose q8hr (max 4 mg/dose) PRN nausea/ vomiting Polyethylene glycol 17 g daily or BID PRN constipation Docusate sodium 50 mg/day PRN constipation	 OT/PT: activity 1 include OOB wit EVD clamped fo therapies if stat and tolerating clamping SCD/compressic boots for DVT p per hospital pol Incentive spirometer or bubbles for atelectasis/PNA prevention
ectious iea se (ID) ntinue empiric tibiotics ancomycin d Ceftazidime) 4 hours or per recs just tibiotics based culture and ID is a notibiotics d, consider m IV access.	 CSF studies: cell count and culture to lab per Neurosurgery and/or ID If CSF culture positive, repeat in 24-36 hours to document sterilization. If persistently febrile or clinica deterioration: repeat CSF culture is warranted. Consider blood, urine and respiratory evaluation. Monitoring: Continuous CR monitoring Vitals q1hr if unstable; q2hr in PICU if stable; q4hr on MS floors 	 Nephrology for approval. Toradol IV 0.5 mg/kg/dose q6hr (max 30 mg/dose) x6 doses 6 hours after last toradol dose, start ibuprofen PO 10 mg/kg/dose q6hr PRN (max 40 mg/kg/day or 2,400 mg/day, whichever is less) Acetaminophen IV 15 mg/kg/dose q6hr ATC for 24 hours (max 1,000 mg/dose) After 24 hours of IV acetaminophen, switch to PO acetaminophen: 15 mg/kg/dose q6hr PRN pain; (max 75 mg/kg/dose rq6hr ATC for 24 hours of IV acetaminophen, switch to PO acetaminophen for infants. Morphine IV 0.05 – 0.1 mg/kg/dose IV q3hr PRN severe pain (max 5 mg/kg/dose) Internalization Criteria: ement and duration of antibiotics with Neurosurgery and ID rance of end-organ space infections. If still present, will consi 	IVF: Maintenance IVF NS 1:1 replacement with CSF output Medications: Ondansetron 0.1 mg/kg/dose q8hr (max 4 mg/dose) PRN nausea/ vomiting Polyethylene glycol 17 g daily or BID PRN constipation Docusate sodium 50 mg/day PRN constipation	 OT/PT: activity 1 include OOB wit EVD clamped fo therapies if stat and tolerating clamping SCD/compressic boots for DVT p per hospital pol Incentive spirometer or bubbles for atelectasis/PNA prevention
ectious sease (ID) ntinue empiric tibiotics ancomycin d Ceftazidime) 4 hours or per recs just tibiotics based culture and ID cs <i>a</i> antibiotics <i>d</i> , consider <i>m</i> IV access.	 CSF studies: cell count and culture to lab per Neurosurgery and/or ID If CSF culture positive, repeat in 24-36 hours to document sterilization. If persistently febrile or clinica deterioration: repeat CSF culture is warranted. Consider blood, urine and respiratory evaluation. Monitoring: Continuous CR monitoring Vitals q1hr if unstable; q2hr in PICU if stable; q4hr on MS floors 	 Nephrology for approval. Toradol IV 0.5 mg/kg/dose q6hr (max 30 mg/dose) x6 doses 6 hours after last toradol dose, start ibuprofen PO 10 mg/kg/dose q6hr PRN (max 40 mg/kg/day or 2,400 mg/day, whichever is less) Acetaminophen IV 15 mg/kg/dose q6hr ATC for 24 hours (max 1,000 mg/dose) After 24 hours of IV acetaminophen, switch to PO acetaminophen: 15 mg/kg/dose q6hr PRN pain; (max 75 mg/kg/dose q6hr PRN pain; (max 75 mg/kg/dose IV q3hr PRN severe pain (max 5 mg/kg/dose IV q3hr PRN severe pain (max 5 mg/dose) Morphine IV 0.05 – 0.1 mg/kg/dose IV q3hr PRN severe pain (max 5 mg/dose) 	IVF: Maintenance IVF NS 1:1 replacement with CSF output Medications: Ondansetron 0.1 mg/kg/dose q8hr (max 4 mg/dose) PRN nausea/ vomiting Polyethylene glycol 17 g daily or BID PRN constipation Docusate sodium 50 mg/day PRN constipation based on clinical status and der alternate site if possible	 OT/PT: activity 1 include OOB wit EVD clamped fo therapies if stat and tolerating clamping SCD/compressic boots for DVT p per hospital pol Incentive spirometer or bubbles for atelectasis/PNA prevention
ectious sease (ID) ntinue empiric tibiotics ancomycin d Ceftazidime) 4 hours or per recs just tibiotics based culture and ID cs <i>a</i> antibiotics <i>d</i> , consider <i>m</i> IV access.	 CSF studies: cell count and culture to lab per Neurosurgery and/or ID If CSF culture positive, repeat in 24-36 hours to document sterilization. If persistently febrile or clinica deterioration: repeat CSF culture is warranted. Consider blood, urine and respiratory evaluation. Monitoring: Continuous CR monitoring Vitals q1hr if unstable; q2hr in PICU if stable; q4hr on MS floors 	 Nephrology for approval. Toradol IV 0.5 mg/kg/dose q6hr (max 30 mg/dose) x6 doses 6 hours after last toradol dose, start ibuprofen PO 10 mg/kg/dose q6hr PRN (max 40 mg/kg/day or 2,400 mg/day, whichever is less) Acetaminophen IV 15 mg/kg/dose q6hr ATC for 24 hours (max 1,000 mg/dose) After 24 hours of IV acetaminophen, switch to PO acetaminophen: 15 mg/kg/dose q6hr PRN pain; (max 75 mg/kg/dose q6hr PRN pain; (max 75 mg/kg/dose IV q3hr PRN severe pain (max 5 mg/dose) Morphine IV 0.05 – 0.1 mg/kg/dose IV q3hr PRN severe pain (max 5 mg/dose) Internalization Criteria: ement and duration of antibiotics with Neurosurgery and ID rance of end-organ space infections. If still present, will consi Post-Op care: to MS floors and resume all pre-internalization care and start 	IVF: Maintenance IVF NS 1:1 replacement with CSF output Medications: Ondansetron 0.1 mg/kg/dose q8hr (max 4 mg/dose) PRN nausea/ vomiting Polyethylene glycol 17 g daily or BID PRN constipation Docusate sodium 50 mg/day PRN constipation	 OT/PT: activity finclude OOB with EVD clamped for therapies if state and tolera ting clamping SCD/compressite boots for DVT pper hospital pol Incentive spirometer or bubbles for atelectasis/PNA prevention
ectious iea se (ID) ntinue empiric tibiotics ancomycin d Ceftazidime) 4 hours or per recs just tibiotics based culture and ID is a notibiotics d, consider m IV access.	 CSF studies: cell count and culture to lab per Neurosurgery and/or ID If CSF culture positive, repeat in 24-36 hours to document sterilization. If persistently febrile or clinica deterioration: repeat CSF culture is warranted. Consider blood, urine and respiratory evaluation. Monitoring: Continuous CR monitoring Vitals q1hr if unstable; q2hr in PICU if stable; q4hr on MS floors 	 Nephrology for approval. Toradol IV 0.5 mg/kg/dose q6hr (max 30 mg/dose) x6 doses 6 hours after last toradol dose, start ibuprofen PO 10 mg/kg/dose q6hr PRN (max 40 mg/kg/day or 2,400 mg/day, whichever is less) Acetaminophen IV 15 mg/kg/dose q6hr ATC for 24 hours (max 1,000 mg/dose) After 24 hours of IV acetaminophen, switch to PO acetaminophen: 15 mg/kg/dose q6hr PRN pain; (max 75 mg/kg/dose q6hr PRN pain; (max 75 mg/kg/dose IV q3hr PRN severe pain (max 5 mg/kg/dose IV q3hr PRN severe pain (max 5 mg/dose) Morphine IV 0.05 – 0.1 mg/kg/dose IV q3hr PRN severe pain (max 5 mg/dose) 	IVF: Maintenance IVF NS 1:1 replacement with CSF output Medications: Ondansetron 0.1 mg/kg/dose q8hr (max 4 mg/dose) PRN nausea/ vomiting Polyethylene glycol 17 g daily or BID PRN constipation Docusate sodium 50 mg/day PRN constipation based on clinical status and der alternate site if possible art incision; may shower POD 3	 OT/PT: activity include OOB with EVD clamped for therapies if state and tolerating clamping SCD/compressite boots for DVT per hospital pol Incentive spirometer or bubbles for atelectasis/PNA prevention
ectious sease (ID) ntinue empiric tibiotics ancomycin d Ceftazidime) 4 hours or per recs just tibiotics based culture and ID cs <i>a</i> antibiotics <i>d</i> , consider <i>m</i> IV access.	 CSF studies: cell count and culture to lab per Neurosurgery and/or ID If CSF culture positive, repeat in 24-36 hours to document sterilization. If persistently febrile or clinica deterioration: repeat CSF culture is warranted. Consider blood, urine and respiratory evaluation. Monitoring: Continuous CR monitoring Vitals q1hr if unstable; q2hr in PICU if stable; q4hr on MS floors 	 Nephrology for approval. Toradol IV 0.5 mg/kg/dose q6hr (max 30 mg/dose) x6 doses 6 hours after last toradol dose, start ibuprofen PO 10 mg/kg/dose q6hr PRN (max 40 mg/kg/day or 2,400 mg/day, whichever is less) Acetaminophen IV 15 mg/kg/dose q6hr ATC for 24 hours (max 1,000 mg/dose) After 24 hours of IV acetaminophen, switch to PO acetaminophen: 15 mg/kg/dose q6hr PRN pain; (max 75 mg/kg/dose q6hr PRN pain; (max 75 mg/kg/dose IV q3hr PRN severe pain (max 5 mg/dose) Morphine IV 0.05 – 0.1 mg/kg/dose IV q3hr PRN severe pain (max 5 mg/dose) Internalization Criteria: ement and duration of antibiotics with Neurosurgery and ID rance of end-organ space infections. If still present, will consi Post-Op care: to MS floors and resume all pre-internalization care and start 	IVF: Maintenance IVF NS 1:1 replacement with CSF output Medications: Ondansetron 0.1 mg/kg/dose q8hr (max 4 mg/dose) PRN nausea/ vomiting Polyethylene glycol 17 g daily or BID PRN constipation Docusate sodium 50 mg/day PRN constipation based on clinical status and der alternate site if possible art incision; may shower POD 3	 OT/PT: activity finclude OOB with EVD clamped for therapies if state and tolera ting clamping SCD/compressite boots for DVT pper hospital pol Incentive spirometer or bubbles for atelectasis/PNA prevention
ectious sease (ID) ntinue empiric tibiotics ancomycin d Ceftazidime) 4 hours or per recs just tibiotics based culture and ID cs <i>a</i> antibiotics <i>d</i> , consider <i>m</i> IV access.	 CSF studies: cell count and culture to lab per Neurosurgery and/or ID If CSF culture positive, repeat in 24-36 hours to document sterilization. If persistently febrile or clinica deterioration: repeat CSF culture is warranted. Consider blood, urine and respiratory evaluation. Monitoring: Continuous CR monitoring Vitals q1hr if unstable; q2hr in PICU if stable; q4hr on MS floors 	Nephrology for approval. • Toradol V 0.5 mg/kg/dose q6hr (max 30 mg/dose) x6 doses • 6 hours after last toradol dose, start ibuprofen PO 10 mg/kg/dose q6hr PRN (max 40 mg/kg/day or 2,400 mg/day, whichever is less) • Acetaminophen IV 15 mg/kg/dose q6hr ATC for 24 hours (max 1,000 mg/dose) • After 24 hours of IV acetaminophen, switch to PO acetaminophen: 15 mg/kg/dose q6hr PRN pRN pain; (max 75 mg/kg/dose q6hr PRN gdose q6hr PRN pain; (max 75 mg/kg/dose q6hr PRN pRN pain; (max 75 mg/kg/dose IV q3hr PRN severe pain (max 5 mg/kg/dose IV q3hr PRN severe pain (max 5 mg/dose) • Morphine IV 0.05 – 0.1 mg/kg/dose IV q3hr PRN severe pain (max 5 mg/dose) • Internalization Criteria: ement and duration of antibiotics with Neurosurgery and ID ance of end-organ space infections. If still present, will consi Post-Op care: • to MS floors and resume all pre-internalization care and statististion, Tegaderm/Telfa to abdominal/chest/clavicular/neck cultures needed unless persistently febrile >36 hours, clinic	 IVF: Maintenance IVF NS 1:1 replacement with CSF output Medications: Ondansetron 0.1 mg/kg/dose q8hr (max 4 mg/dose) PRN nausea/ vomiting Polyethylene glycol 17 g daily or BID PRN constipation Docusate sodium S0 mg/day PRN constipation Docusate sodium S0 mg/day PRN constipation 	OT/PT: activity finclude OOB with EVD clamped for therapies if state and tolera ting clamping SCD/compressite boots for DVT pper hospital pol Incentive spirometer or bubbles for atelectasis/PNA prevention response to therapy. c.
ectious sease (ID) ntinue empiric tibiotics ancomycin d Ceftazidime) 4 hours or per recs just tibiotics based culture and ID cs <i>a</i> antibiotics <i>d</i> , consider <i>m</i> IV access.	 CSF studies: cell count and culture to lab per Neurosurgery and/or ID If CSF culture positive, repeat in 24-36 hours to document sterilization. If persistently febrile or clinica deterioration: repeat CSF culture is warranted. Consider blood, urine and respiratory evaluation. Monitoring: Continuous CR monitoring Vitals q1hr if unstable; q2hr in PICU if stable; q4hr on MS floors 	 Nephrology for approval. Toradol IV 0.5 mg/kg/dose q6hr (max 30 mg/dose) x6 doses 6 hours after last toradol dose, start ibuprofen PO 10 mg/kg/dose q6hr PRN (max 40 mg/kg/day or 2,400 mg/day, whichever is less) Acetaminophen IV 15 mg/kg/dose q6hr ATC for 24 hours (max 1,000 mg/dose) After 24 hours of IV acetaminophen, switch to PO acetaminophen: 15 mg/kg/dose q6hr PRN pain; (max 75 mg/kg/dose q6hr PRN pain; (max 75 mg/kg/dose IV q3hr PRN severe pain (max 5 mg/kg/dose IV q3hr PRN severe pain (max 5 mg/dose) Morphine IV 0.05 – 0.1 mg/kg/dose IV q3hr PRN severe pain (max 5 mg/dose) 	 IVF: Maintenance IVF NS 1:1 replacement with CSF output Medications: Ondansetron 0.1 mg/kg/dose q8hr (max 4 mg/dose) PRN nausea/ vomiting Polyethylene glycol 17 g daily or BID PRN constipation Docusate sodium S0 mg/day PRN constipation Docusate sodium S0 mg/day PRN constipation 	OT/PT: activity finclude OOB with EVD clamped for therapies if state and tolera ting clamping SCD/compressite boots for DVT pper hospital pol Incentive spirometer or bubbles for atelectasis/PNA prevention response to therapy. c.
ectious sease (ID) ntinue empiric tibiotics ancomycin d Ceftazidime) 4 hours or per recs just tibiotics based culture and ID cs <i>a</i> antibiotics <i>d</i> , consider <i>m</i> IV access.	 CSF studies: cell count and culture to lab per Neurosurgery and/or ID If CSF culture positive, repeat in 24-36 hours to document sterilization. If persistently febrile or clinicad deterioration: repeat CSF culture is warranted. Consider blood, urine and respiratory evaluation. Monitoring: Continuous CR monitoring Vitals q1hr if unstable; q2hr in PICU if stable; q4hr on MS floors stitive, discuss timing of shunt replace Terminal sites dependent on clear Transfer Bacitracin to scalp ir replacement or daily 	Nephrology for approval. • Toradol N 0.5 mg/kg/dose q6hr (max 30 mg/dose) x6 doses • 6 hours after last toradol dose, start ibuprofen PO 10 mg/kg/dose q6hr PRN (max 40 mg/kg/day or 2,400 mg/day, whichever is less) • Acetaminophen IV 15 mg/kg/dose q6hr ATC for 24 hours (max 1,000 mg/dose) • After 24 hours of IV acetaminophen, switch to PO acetaminophen: 15 mg/kg/dose q6hr PRN pain; (max 75 mg/kg/dose q0hr PRN pain; (max 75 mg/kg/dose IV q3hr PRN severe pain (max 5 mg/kg/dose IV q3hr PRN severe pain (max 5 mg/dose) • Morphine IV 0.05 – 0.1 mg/kg/dose IV q3hr PRN severe pain (max 5 mg/dose) • Internalization Criteria: ement and duration of antibiotics with Neurosurgery and ID ance of end-organ space infections. If still present, will consi Post-Op care: • to MS floors and resume all pre-internalization care and statisticision, Tegaderm/Telfa to abdominal/chest/clavicular/neck r cultures nee ded unless persistently febrile >36 hours, clinic • warm; pain well controlled on PO meds; afebrile x24 hrs; bow	IVF: Maintenance IVF NS 1:1 replacement with CSF output Medications: Ondansetron 0.1 mg/kg/dose q8hr (max 4 mg/dose) PRN nausea/ vomiting Polyethylene glycol 17 g daily or BID PRN constipation Docusate sodium 50 mg/day PRN constipation based on clinical status and der alternate site if possible and rt incision; may shower POD 3 ally deteriorating rel movement; adequate PO	OT/PT: activity include OOB with EVD clamped for therapies if state and tolerating clamping SCD/compressite boots for DVT per hospital pol Incentive spirometer or bubbles for atelectasis/PNA prevention response to therapy. S; no further CSF
ectious sea se (ID) ntinue empiric tibiotics ancomycin d Ceftazidime) 4 hours or per recs just tibiotics based culture and ID rs <i>i</i> antibiotics <i>j</i> , consider m IV access. CSF culture is po	 CSF studies: cell count and culture to lab per Neurosurgery and/or ID If CSF culture positive, repeat in 24-36 hours to document sterilization. If persistently febrile or clinica deterioration: repeat CSF culture is warranted. Consider blood, urine and respiratory evaluation. Monitoring: Continuous CR monitoring Vitals q1hr if unstable; q2hr in PICU if stable; q4hr on MS floors 	Nephrology for approval. • Toradol N 0.5 mg/kg/dose q6hr (max 30 mg/dose) x6 doses • 6 hours after last toradol dose, start ibuprofen PO 10 mg/kg/dose q6hr PRN (max 40 mg/kg/day or 2,400 mg/day, whichever is less) • Acetaminophen IV 15 mg/kg/dose q6hr ATC for 24 hours (max 1,000 mg/dose) • After 24 hours of IV acetaminophen, switch to PO acetaminophen: 15 mg/kg/dose q6hr PRN pain; (max 75 mg/kg/dose q6hr PRN pain; (max 75 mg/kg/dose IV q3hr PRN severe pain (max 5 mg/dose) • Morphine IV 0.05 – 0.1 mg/kg/dose IV q3hr PRN severe pain (max 5 mg/dose) • Internalization Criteria: ement and duration of antibiotics with Neurosurgery and ID rance of end-organ space infections. If still present, will consi Post-Op care: • to MS floors and resume all pre-internalization care and staticision, Tegaderm/Telfa to abdominal/chest/clavicular/neck cultures nee ded unless persistently febrile >36 hours, clinic • warm; pain well controlled on PO meds; afebrile x24 hrs; bow Discharge Instructions/Medications:	IVF: Maintenance IVF NS 1:1 replacement with CSF output Medications: Ondansetron 0.1 mg/kg/dose q8hr (max 4 mg/dose) PRN nausea/ vomiting Polyethylene glycol 17 g daily or BID PRN constipation Docusate sodium 50 mg/day PRN constipation based on clinical status and der alternate site if possible art: incision; may shower POD 3 ally deteriorating rel movement; adequate PO Ymoderate pain, Acetaminoj	OT/PT: activity include OOB with EVD clamped for therapies if state and tolerating clamping SCD/compression boots for DVT pure hospital pol Incentive spirometer or bubbles for atelectasis/PNA prevention response to therapy. State of the angle o
ectious ease (ID) ntinue empiric tibiotics ancomycin d Ceftazidime) 4 hours or per recs just tibiotics based culture and ID is <i>cantibiotics</i> <i>d, consider</i> <i>m IV access.</i> CSF culture is po CSF culture is po lbuprof q6hr PR Follow	 CSF studies: cell count and culture to lab per Neurosurgery and/or ID If CSF culture positive, repeat in 24-36 hours to document sterilization. If persistently febrile or clinica deterioration: repeat CSF culture is warranted. Consider blood, urine and respiratory evaluation. Monitoring: Continuous CR monitoring Vitals q1hr if unstable; q2hr in PICU if stable; q4hr on MS floors 	Nephrology for approval. • Toradol N 0.5 mg/kg/dose q6hr (max 30 mg/dose) x6 doses • 6 hours after last toradol dose, start ibuprofen PO 10 mg/kg/dose q6hr PRN (max 40 mg/kg/day or 2,400 mg/day, whichever is less) • Acetaminophen IV 15 mg/kg/dose q6hr ATC for 24 hours (max 1,000 mg/dose) • After 24 hours of IV acetaminophen, switch to PO acetaminophen. 15 mg/kg/dose q6hr PRN pain; (max 75 mg/kg/dose q6hr 4,000 mg/ day) for mild/moderate pain; may use PR acetaminophen for infants. • Morphine IV 0.05 − 0.1 mg/kg/dose IV q3hr PRN severe pain (max 5 mg/dose) • Internalization Criteria: ement and duration of antibiotics with Neurosurgery and ID ance of end-organ space infections. If still present, will consi Post-Op care: • to MS floors and resume all pre-internalization care and statistics ion, Tegaderm/Telfa to abdominal/chest/clavicular/neck v cultures nee ded unless persistently febrile >36 hours, clinic • w • x 40 mg/kg/day or 2,400 mg/day, whichever is less) for mild, mg/day) for mild/moderate pain; Polyethylene glycol PO an	VF: Maintenance IVF NS 1:1 replacement with CSF output Medications: Ondansetron 0.1 mg/kg/dose q8hr (max 4 mg/dose) PRN nausea/ vomiting Polyethylene glycol 17 g daily or BID PRN constipation Docusate sodium 50 mg/day PRN constipation based on clinical status and der alternate site if possible art: incision; may shower POD 3 ally deteriorating rel movement; adequate PO moderate pain, Acetaminoj d/or Docusate to prevent co	OT/PT: activity include OOB with EVD clamped for therapies if state and tolerating clamping SCD/compression boots for DVT pure hospital pol Incentive spirometer or bubbles for atelectasis/PNA prevention response to therapy. State of the angle o
ecs ty antibiotics td, consider tm IV access. f CSF culture is po f CSF culture is po buppof q6hr PR Follow	 CSF studies: cell count and culture to lab per Neurosurgery and/or ID If CSF culture positive, repeat in 24-36 hours to document sterilization. If persistently febrile or clinica deterioration: repeat CSF culture is warranted. Consider blood, urine and respiratory evaluation. Monitoring: Continuous CR monitoring Vitals q1hr if unstable; q2hr in PICU if stable; q4hr on MS floors 	Nephrology for approval. • Toradol V 0.5 mg/kg/dose q6hr (max 30 mg/dose) x6 doses • 6 hours after last toradol dose, start ibuprofen PO 10 mg/kg/dose q6hr PRN (max 40 mg/kg/day or 2,400 mg/day, whichever is less) • Acetaminophen IV 15 mg/kg/dose q6hr ATC for 24 hours (max 1,000 mg/dose) • After 24 hours of IV acetaminophen, switch to PO acetaminophen: 15 mg/kg/dose q6hr PRN pain; (max 75 mg/kg/dose IV q3hr PRN gay) for mild/moderate pain; may use PR acetaminophen for infants. • Morphine IV 0.05 – 0.1 mg/kg/dose IV q3hr PRN severe pain (max 5 mg/kg/dose) • Internalization Criteria: tement and duration of antibiotics with Neurosurgery and ID rance of end-organ space infections. If still present, will consi Post-Op care: • to MS floors and resume all pre-internalization care and staticision, Tegaderm/Telfa to abdominal/chest/clavicular/neck • cultures needed unless persistently febrile >36 hours, clinic • warm; pain well controlled on PO meds; afebrile x24 hrs; bow Discharge Instructions/Medications: x 40 mg/kg/day or 2,400 mg/day, whichever is less) for mild/	VF: Maintenance IVF NS 1:1 replacement with CSF output Medications: Ondansetron 0.1 mg/kg/dose q8hr (max 4 mg/dose) PRN nausea/ vomiting Polyethylene glycol 17 g daily or BID PRN constipation Docusate sodium 50 mg/day PRN constipation based on clinical status and der alternate site if possible art: incision; may shower POD 3 ally deteriorating rel movement; adequate PO moderate pain, Acetaminoj d/or Docusate to prevent co	OT/PT: activity include OOB will EVD clamped fit therapies if sta and tolerating clamping SCD/compressi boots for DVT p per hospital poo Incentive spirometer or bubbles for atelectasis/PN/ prevention response to therapy. State of the s



Connecticut Children's

Important factors to consider include:

- Shunt Type:
 - o ventricular-atrial shunt
 - o ventricular-plural shunt
 - ventricular-peritoneal shunt
- Headache History:
 - o location
 - o quality
 - o duration
 - o **treatment**
- Vomiting History:
 - o timing
 - o any precipitating events
- Neurological symptoms:
 - o change in LOC
 - ↑ irritability
 - o weakness
 - o seizures
 - o up/downward gaze
 - ↑ lethargy

Abdominal symptoms:

- significant ↑ abdominal girth
- o pain
- o tenderness
- o mass
- General:
 - o **trauma**
 - o fontanels
 - head circumference
 - $\circ \downarrow$ breath sounds for pleural shunts






When evaluating the radiographic markings of any implanted device, it is important to recognize that the veracity of your interpretation depends on the quality of the radiographic images. For the best results, x-rays should be taken orthogonally to the plane of the shunt valve. The positioning of the valve relative to the skull base may also obscure the valve markings, as overlapping radiodensities along the skull base can blur valve markings. In more difficult cases, fluoroscopy or 3D CT reconstruction may be used to properly identify the radio-opaque markings on a shunt valve.

It is important to realize that an exhaustive list of all shunt valve radiographic markings is beyond the scope of this appendix. For additional information regarding common shunt valve markings found in North American neurosurgical patients, you may also reference the <u>ISPN's website</u> on the same topic.

Please see the next several pages for examples of radiographic images of nonprogrammable and programmable shunts. The sources of these images are:

- <u>http://www.kinderneurochirurgie-leipzig.de/therapeuticfocus/hydrocephalus/radiologic-identification-of-vp-shunt-valves-and-adjustment/</u>
- <u>https://www.ispn.guide/</u>
- https://www.medtronic.com/us-en/index.html
- <u>https://radiopaedia.org/</u>


Non-Programmable Valve Examples:



Medtronic Delta Fixed Pressure Valve







Medtronic PS Medical Pressure Differential Valve (non-programmable)




Spitz-Holter Non-Programmable Valve





CLINICAL PATHWAY: Suspected Neurosurgical Shunt Infection Appendix B: Radiographic Appearance of Shunt Valves

Integra Omni Shunt Fixed Pressure Valve




Integra DP Fixed Pressure Valve








Programmable Valve Examples:



Strata Programmable Valve



Codman Hakim Programmable Shunt Valve






CLINICAL PATHWAY: Suspected Neurosurgical Shunt Infection Appendix B: Radiographic Appearance of Shunt Valves

THIS PATHWAY SERVES AS A GUIDE AND DOES NOT REPLACE CLINICAL JUDGMENT.



Unidentified Programmable Valve (likely Sophysa model)




ProGrav Adjustable Valve

RETURN TO THE BEGINNING



CLINICAL PATHWAY: Suspected Neurosurgical Shunt Infection Appendix B: Radiographic Appearance of Shunt Valves

THIS PATHWAY SERVES AS A GUIDE AND DOES NOT REPLACE CLINICAL JUDGMENT.



Sophysa Programmable Valve



Certas Programmable Valve

RETURN TO THE BEGINNING

CONTACTS: JONATHAN MARTIN, MD | PETRONELLA STOLTZ, APRN



©2019 Connecticut Children's Medical Center. All rights reserved.